Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1A | P07327 | 12/20 | 0.94 |
| ▸ | ADH1C | P00326 | 9/20 | 0.94 |
| ▸ | ADH4 | P08319 | 2/20 | 0.94 |
| ▸ | ADH1B | P00325 | 2/20 | 0.41 |
| ▸ | ADH7 | P40394 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6005197 | 0.97 | ADH1A (1.00) | ADH1AADH1CADH4ADH1BADH7 | |
| SCHEMBL4496323 | 0.97 | ADH1A (1.00) | ADH1AADH1CADH4ADH1BADH7 | |
| SCHEMBL5122418 | 0.94 | ADH1A (1.00) | ADH1AADH1CADH4ADH1BADH7 | |
| SCHEMBL3160136 | 0.94 | ADH1A (1.00) | ADH1AADH1CADH4ADH1BADH7 | |
| Cyclobutyl(Cyclopentyl)Formamide SCHEMBL4315833 | 0.94 | ADH1A (1.00) | ADH1AADH1CADH4ADH1BADH7 | |
| SCHEMBL2874295 | 0.94 | — | — | |
| SCHEMBL10012570 | 0.91 | ADH1A (0.94) | ADH1AADH1CADH4ADH1BADH7 | |
| SCHEMBL10013014 | 0.91 | ADH1A (0.94) | ADH1AADH1CADH4ADH1BADH7 | |
| SCHEMBL14855293 | 0.91 | ADH1A (0.94) | ADH1AADH1CADH4ADH1BADH7 | |
| SCHEMBL10913207 | 0.91 | ADH1A (0.94) | ADH1AADH1CADH4ADH1BADH7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2700643-B1 | TETRAHYDROTHIAZEPINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2016-11-23 | — | — | EP | disclosed |
| US-8927536-B2 | Tetrahydrothiazepine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-01-06 | — | — | US | disclosed |
| US-20140080808-A1 | TETRAHYDROTHIAZEPINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-03-20 | — | — | US | disclosed |
| EP-2700643-A1 | TETRAHYDROTHIAZEPINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-02-26 | — | — | EP | disclosed |
| EP-1207161-B1 | NOVEL ISOINDOLE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2006-01-18 | — | — | EP | disclosed |
| US-6777410-B2 | SUCH AS 9-(2-METHOXYPHENYL)-3-(1-METHYLETHYL)-(1,3)OXAZOLO-(2,3)ISOINDOLE-2,5(3H,9H)-DIONE; DIABETES AND COMPLICATIONS; OBESITY | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-08-17 | — | — | US | disclosed |
| US-20040053923-A1 | Novel isoindole derivatives | BANYU PHARMACEUTICAL CO., LTD. | 2004-03-18 | — | — | US | disclosed |
| US-6608098-B1 | Diabetes or obesity, 2-(4-(3-isopropyl-2,5-dioxo-2,3-dihydro-1H-pyrrolo(2,1-a) isoindol-9(5H)-yl)phenoxy)-N-propylacetamide | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-08-19 | — | — | US | disclosed |
| EP-1207161-A1 | NOVEL ISOINDOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-05-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080808-A1 | TETRAHYDROTHIAZEPINE DERIVATIVE | HSD11B1, HSD11B2, HSD3B1 | ADH1A 26/4885ADH1C 30/4885ADH4 77/4885 |
| US-20040053923-A1 | Novel isoindole derivatives | GPR119, SLC5A2, SLC5A1 | ADH1A 98/4885ADH1C 89/4885ADH4 431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.